106 related articles for article (PubMed ID: 12589033)
1. p53-independent response to cisplatin and oxaliplatin in MMTV-ras mouse salivary tumors.
Petit T; Bearss DJ; Troyer DA; Munoz RM; Windle JJ
Mol Cancer Ther; 2003 Feb; 2(2):165-71. PubMed ID: 12589033
[TBL] [Abstract][Full Text] [Related]
2. Genetic determinants of response to chemotherapy in transgenic mouse mammary and salivary tumors.
Bearss DJ; Subler MA; Hundley JE; Troyer DA; Salinas RA; Windle JJ
Oncogene; 2000 Feb; 19(8):1114-22. PubMed ID: 10713698
[TBL] [Abstract][Full Text] [Related]
3. A farnesyltransferase inhibitor induces tumor regression in transgenic mice harboring multiple oncogenic mutations by mediating alterations in both cell cycle control and apoptosis.
Barrington RE; Subler MA; Rands E; Omer CA; Miller PJ; Hundley JE; Koester SK; Troyer DA; Bearss DJ; Conner MW; Gibbs JB; Hamilton K; Koblan KS; Mosser SD; O'Neill TJ; Schaber MD; Senderak ET; Windle JJ; Oliff A; Kohl NE
Mol Cell Biol; 1998 Jan; 18(1):85-92. PubMed ID: 9418856
[TBL] [Abstract][Full Text] [Related]
4. Increased tumor proliferation and genomic instability without decreased apoptosis in MMTV-ras mice deficient in p53.
Hundley JE; Koester SK; Troyer DA; Hilsenbeck SG; Subler MA; Windle JJ
Mol Cell Biol; 1997 Feb; 17(2):723-31. PubMed ID: 9001226
[TBL] [Abstract][Full Text] [Related]
5. Differential effects of p21(WAF1/CIP1) deficiency on MMTV-ras and MMTV-myc mammary tumor properties.
Bearss DJ; Lee RJ; Troyer DA; Pestell RG; Windle JJ
Cancer Res; 2002 Apr; 62(7):2077-84. PubMed ID: 11929828
[TBL] [Abstract][Full Text] [Related]
6. Comparison of effects of p53 null and gain-of-function mutations on salivary tumors in MMTV-Hras transgenic mice.
Jiang D; Dumur CI; Massey HD; Ramakrishnan V; Subler MA; Windle JJ
PLoS One; 2015; 10(2):e0118029. PubMed ID: 25695772
[TBL] [Abstract][Full Text] [Related]
7. Differential regulation of cell cycle characteristics and apoptosis in MMTV-myc and MMTV-ras mouse mammary tumors.
Hundley JE; Koester SK; Troyer DA; Hilsenbeck SG; Barrington RE; Windle JJ
Cancer Res; 1997 Feb; 57(4):600-3. PubMed ID: 9044833
[TBL] [Abstract][Full Text] [Related]
8. Increased sensitivity of p53-deficient cells to anticancer agents due to loss of Pms2.
Fedier A; Ruefenacht UB; Schwarz VA; Haller U; Fink D
Br J Cancer; 2002 Oct; 87(9):1027-33. PubMed ID: 12434296
[TBL] [Abstract][Full Text] [Related]
9. Oxaliplatin-induced gamma-H2AX activation via both p53-dependent and -independent pathways but is not associated with cell cycle arrest in human colorectal cancer cells.
Chiu SJ; Lee YJ; Hsu TS; Chen WS
Chem Biol Interact; 2009 Dec; 182(2-3):173-82. PubMed ID: 19735649
[TBL] [Abstract][Full Text] [Related]
10. Reactivating p53 and Inducing Tumor Apoptosis (RITA) Enhances the Response of RITA-Sensitive Colorectal Cancer Cells to Chemotherapeutic Agents 5-Fluorouracil and Oxaliplatin.
Wiegering A; Matthes N; Mühling B; Koospal M; Quenzer A; Peter S; Germer CT; Linnebacher M; Otto C
Neoplasia; 2017 Apr; 19(4):301-309. PubMed ID: 28284059
[TBL] [Abstract][Full Text] [Related]
11. Antitumour activity of oxaliplatin in neuroblastoma cell lines.
Riccardi A; Ferlini C; Meco D; Mastrangelo R; Scambia G; Riccardi R
Eur J Cancer; 1999 Jan; 35(1):86-90. PubMed ID: 10211093
[TBL] [Abstract][Full Text] [Related]
12. Apoptosis and growth arrest induced by platinum compounds in U2-OS cells reflect a specific DNA damage recognition associated with a different p53-mediated response.
Gatti L; Supino R; Perego P; Pavesi R; Caserini C; Carenini N; Righetti SC; Zuco V; Zunino F
Cell Death Differ; 2002 Dec; 9(12):1352-9. PubMed ID: 12478472
[TBL] [Abstract][Full Text] [Related]
13. Retained platinum uptake and indifference to p53 status make novel transplatinum agents active in platinum-resistant cells compared to cisplatin and oxaliplatin.
Murphy RF; Komlodi-Pasztor E; Robey R; Balis FM; Farrell NP; Fojo T
Cell Cycle; 2012 Mar; 11(5):963-73. PubMed ID: 22333583
[TBL] [Abstract][Full Text] [Related]
14. The relative activity of cisplatin, oxaliplatin and satraplatin in testicular germ cell tumour sensitive and resistant cell lines.
Perry J; Powles T; Shamash J; Veerupillai A; McGrowder E; Noel E; Lu YJ; Oliver T; Joel S
Cancer Chemother Pharmacol; 2009 Oct; 64(5):925-33. PubMed ID: 19263053
[TBL] [Abstract][Full Text] [Related]
15. Tumorigenesis and male sterility in transgenic mice expressing a MMTV/N-ras oncogene.
Mangues R; Seidman I; Pellicer A; Gordon JW
Oncogene; 1990 Oct; 5(10):1491-7. PubMed ID: 2174525
[TBL] [Abstract][Full Text] [Related]
16. Chemoradiation of cervical cancer cells: targeting human papillomavirus E6 and p53 leads to either augmented or attenuated apoptosis depending on the platinum carrier ligand.
Koivusalo R; Krausz E; Ruotsalainen P; Helenius H; Hietanen S
Cancer Res; 2002 Dec; 62(24):7364-71. PubMed ID: 12499281
[TBL] [Abstract][Full Text] [Related]
17. The BH3-only protein, PUMA, is involved in oxaliplatin-induced apoptosis in colon cancer cells.
Wang X; Li M; Wang J; Yeung CM; Zhang H; Kung HF; Jiang B; Lin MC
Biochem Pharmacol; 2006 May; 71(11):1540-50. PubMed ID: 16595125
[TBL] [Abstract][Full Text] [Related]
18. Mutations of p53 and KRAS activate NF-κB to promote chemoresistance and tumorigenesis via dysregulation of cell cycle and suppression of apoptosis in lung cancer cells.
Yang L; Zhou Y; Li Y; Zhou J; Wu Y; Cui Y; Yang G; Hong Y
Cancer Lett; 2015 Feb; 357(2):520-6. PubMed ID: 25499080
[TBL] [Abstract][Full Text] [Related]
19. MMTV-Fgf8 transgenic mice develop mammary and salivary gland neoplasia and ovarian stromal hyperplasia.
Daphna-Iken D; Shankar DB; Lawshé A; Ornitz DM; Shackleford GM; MacArthur CA
Oncogene; 1998 Nov; 17(21):2711-7. PubMed ID: 9840935
[TBL] [Abstract][Full Text] [Related]
20. p73alpha is a candidate effector in the p53 independent apoptosis pathway of cisplatin damaged primary murine colonocytes.
Oniscu A; Sphyris N; Morris RG; Bader S; Harrison DJ
J Clin Pathol; 2004 May; 57(5):492-8. PubMed ID: 15113856
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]